ClinicalTrials.gg
RecruitingNCT07801300Updated Oct 20, 2026

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

A Phase 1 interventional study of LY5625575 and Placebo in Healthy Volunteers and C-Reactive Protein, sponsored by Eli Lilly and Company. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 20, 2026Now RecruitingEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also measure how much LY5625575 gets into the bloodstream and how long it takes the body to get rid of it.

The study will last seven to nine weeks.

02

Conditions studied

  • Healthy Volunteers
  • C-Reactive Protein
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Parts:

    • Individuals not of may participate in this trial.
    • Individuals assigned male at birth may participate in this trial.
    • Healthy as defined by

      • the absence of illness and surgery within 35 days prior to first dosing, and
      • the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  • Part A:

    -- Have an estimated (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation 2021, of greater than or equal to (≥)90 milliliters per minute per 1.73 square meters (mL/min/1.73 m²) at screening.

  • Parts B, C, D, and E:

    -- Have an eGFR, using the CKD-EPI creatinine equation 2021, of ≥60 mL/minute/1.73 m²

  • Parts A, B, D, and E:

    -- Have a ≥18.5 and less than (\<)32.0 kilograms per square meter (kg/m²)

  • Part C:

    • hsCRP ≥2 mg/L and ≤15 mg/L at screening and Day -1.
    • Have a body mass index ≥18.5 and \<40.0 m².
  • Part D:

    -- To qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

  • Part E:

    • To qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China.

Exclusion criteria

Exclusion Criteria:

  • All Parts:

    • Individuals of are excluded from the trial
    • Any abnormal finding at physical examination at screening and/or Day -1.
    • Any clinically significant physical findings in the mouth or tongue (for example, difficulty swallowing) that would be likely to interfere with oral administration of study intervention.
    • History of significant allergic reactions (for example, anaphylactic reaction, , or angioedema) to any medication or known allergic reactions to drugs related to LY5625575, or to any in the formulation.
    • History of active tuberculosis or presence of active or latent tuberculosis.
    • History or evidence of clinically significant opportunistic infection (for example, invasive candidiasis or pneumocystis pneumonia).
    • History of serious local infection (for example, cellulitis or abscess) or systemic infection (for example, septicemia) within 90 days prior to screening.
    • History of nonserious but active infections
    • History of more than one episode of herpes zoster infection or history of disseminated herpes zoster infection.
    • Presence or history of any abnormality or illness, which in the opinion of the investigator may affect absorption, distribution, metabolism, or elimination of the study intervention.
    • Are currently enrolled in a clinical study involving an medicinal product (IMP) or any other type of medical research judged not to be scientifically or medically compatible with this study.
    • Are currently enrolled in or past participation in a clinical study involving a study intervention for which at least 5 half-lives or 30 days (whichever is longer) have not passed prior to screening.
    • Participation in a clinical study involving an investigational medicinal product (IMP) with an unknown half-life within the 12 months prior to screening.
    • Have a 12-lead echocardiogram () abnormality that, in the opinion of the investigator,

      • increases the risks associated with participating in the study
      • may confound ECG data analysis
    • Have blood pressure and/or pulse rate constituting a risk when taking the investigational medicinal product, as determined by the investigator.
    • Clinically significant abnormal laboratory test results at screening, or positive serology test results for surface antigen, hepatitis B core total antibody, virus antibody, or antigen and antibody, or QuantiFERON®-TB test at screening
    • Positive pregnancy test or lactating participants assigned female at birth at screening and/or Day -1.
    • Positive drug screen, cotinine test, or alcohol test at screening and/or Day -1.
    • Any screening laboratory evaluation outside the laboratory reference range that is judged by the investigator to be clinically significant, with the exception of (AST), alanine aminotransferase (ALT), and/or total (TBL) greater than (>) (ULN) for these laboratory parameters.
    • Presence of fever (body temperature >37.6°C) (for example, a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to first dosing.
    • Use of medications for the timeframes specified below, with the exception of medications exempted by the investigator on a case-by-case basis because they are judged unlikely to affect the pharmacokinetic (PK) profile of the study intervention or participant safety (for example, topical drug products without significant systemic exposure):

      • depot injection or implant for 90 days prior to dosing
      • biologics for 90 days (or 5 half-lives, whichever is longer) prior to first dosing
      • for 30 days prior to dosing
      • prescription medications or over-the-counter (OTC) medications and natural health products (including herbal remedies such as St. John's wort, homeopathic and traditional medicines, probiotics, food supplements such as amino acids, essential fatty acids, and protein supplements used in sports, with the exception of vitamins and minerals) for 14 days (or 5 half-lives, whichever is longer) prior to dosing (acetaminophen ≤3 grams/day will be permitted), or
      • any vaccine, including coronavirus disease 2019 (COVID-19) vaccine, for 14 days prior to dosing.
    • History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine, crack, opioid derivatives including heroin, and amphetamine derivatives) within 90 days prior to screening.
    • Any use of tobacco and/or nicotine product within 90 days prior to screening.
    • Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation, or an amount deemed significant by the investigator.
    • Have donated blood of more than 500 mL within the previous 90 days of screening or intend to donate blood during the course of the study.
  • Parts B, C, D, and E:

    • Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
    • Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 90 days (at screening and/or Day -1) OR
    • Have answered "yes" to any of the suicide-related behaviors on the "Suicidal Behavior" portion of the C-SSRS and the behavior occurred within the past 90 days (at screening and/or Day -1). NOTE: Non-suicidal self-injurious behavior is not considered a suicide-related behavior.
    • Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    LY5625575 (Part A) - Single Dose Healthy

    Single escalating doses of LY5625575 administered orally in healthy participants.

    Drug: LY5625575

  • Placebo comparator
    Placebo (Part A) - Single Dose Healthy

    Single dose of placebo administered orally in healthy participants.

    Drug: Placebo

  • Experimental
    LY5625575 (Part B) - Multiple Dose Healthy

    Two or more doses of LY5625575 administered orally in healthy participants.

    Drug: LY5625575

  • Placebo comparator
    Placebo (Part B) - Multiple Dose Healthy

    Two or more doses of placebo administered orally in healthy participants.

    Drug: Placebo

  • Experimental
    LY5625575 (Part C) - Multiple Dose Elevated hsCRP

    Two or more doses of LY5625575 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP).

    Drug: LY5625575

  • Placebo comparator
    Placebo (Part C) - Multiple Dose Elevated hsCRP

    Two or more doses of placebo administered orally in participants with elevated hsCRP.

    Drug: Placebo

  • Experimental
    LY5625575 (Part D) - Multiple Dose Healthy Japanese

    Two or more doses of LY5625575 administered orally in healthy Japanese participants.

    Drug: LY5625575

  • Placebo comparator
    Placebo (Part D) - Multiple Dose Healthy Japanese

    Two or more doses of placebo administered orally in healthy Japanese participants

    Drug: Placebo

  • Experimental
    LY5625575 (Part E) - Multiple Dose Healthy Chinese

    Two or more doses of LY5625575 administered orally in healthy Chinese participants.

    Drug: LY5625575

  • Placebo comparator
    Placebo (Part E) - Multiple Dose Healthy Chinese

    Two or more doses of placebo administered orally in healthy Chinese participants.

    Drug: Placebo

Interventions

  • DrugLY5625575

    Administered orally.

    Also known as: ZMG-3003936

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module

    Time frame: Baseline up to Day 24

Secondary outcomes

  1. Pharmacokinetics (PK): Area under the Concentration Versus Time Curve (AUC) of LY5625575

    Time frame: Day 1 Predose up to Day 17

07

Study locations

1 of 2 sites recruiting
  • Syneos Health
    Miami, Florida 33136, United States
    Recruiting
    • · Contact305-547-5800
    • Monica Mauri · Principal investigator
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
    Not yet recruiting
    • · Contact214-647-9375
    • Archie Bowie · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 3, 2026
StartActual
Sep 2, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Syneos Health · Miami, United Statesno status→Recruiting
  • Fortrea Clinical Research Unit · Dallas, United Statesno status→Not yet recruiting
Oct 9, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedHave a body mass index ≥18.5 and <40.0 m2m².
Exclusion criteria
  • EditedAre currently enrolled in or past participation within the 30 days prior to screening, in a clinical study involving a study intervention for which at least 5 half-lives or 30 days (whichever is longer) have not passed prior to screening.
  • AddedParticipation in a clinical study involving an investigational medicinal product (IMP) with an unknown half-life within the 12 months prior to screening.
Oct 20, 2026
Show all 2 updates
  1. Oct 20, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedHave a body mass index ≥18.5 and <40.0 m2m².
    Exclusion criteria
    • EditedAre currently enrolled in or past participation within the 30 days prior to screening, in a clinical study involving a study intervention for which at least 5 half-lives or 30 days (whichever is longer) have not passed prior to screening.
    • AddedParticipation in a clinical study involving an investigational medicinal product (IMP) with an unknown half-life within the 12 months prior to screening.
  2. Oct 9, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Syneos Health · Miami, United Statesno status→Recruiting
    • Fortrea Clinical Research Unit · Dallas, United Statesno status→Not yet recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07801300
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Sep 2, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion